Clinical Trial Update: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 trial evaluating IMCgp100 in combination with durvalumab and/or tremelimumab for advanced cutaneous melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Durvalumab (durvalumab)
• IMCgp100 (tebentafusp) (tebentafusp)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Immunocore Ltd | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN